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Long-term studies show that type 2 diabetes is associated with a progres-
sive deterioration of glucose tolerance. After a median time of approx. 9 
years most people with type 2 diabetes require the addition of insulin to 
anti-diabetic oral agents to achieve optimal glycemic control. Currently 
there is no strong evidence for a specific insulin regimen for initiating in-
sulin treatment in type 2 diabetes. Therefore, different regimens for the 
initiation of insulin treatment are coexisting in clinical care: (1) Basal in-
sulin supported Oral Therapy (BOT), (2) Supplementary Insulin Treatment 
with prandial insulin (SIT), and (3) Conventional Insulin Treatment with 
biphasic insulin (CT). These different insulin regimens are requiring new 
skills and knowledge in people with type 2 diabetes, previously treated 
with lifestyle modification and oral anti-diabetic agents. Amongst these 
new skills are the correct injection and dosing of insulin, blood glucose 
self-control and the timing of insulin injection with carbohydrate intake 
in prandial or biphasic insulin regimens. MEDIAS 2 BOT+SIT+CT (More Di-
abetes Selfmanagement for People with type 2 diabetes on a BOT, SIT 
or CT) is a newly developed diabetes education and treatment program-
me for people with type 2 diabetes (PWD-T2) on a non-intensive insulin 
treatment regimen. The development of MEDIAS 2 BOT+SIT+CT (MEDIAS 
2 BSC) was based on the self-management and empowerment theory. 
The efficacy of the newly developed intervention MEDIAS 2 BSC  was eva-
luated in a randomized trial with a 6-month follow-up period. The control 
group (CG) participated in an established education programme (treat-
ment- and education programme for type 2 diabetic patients with injec-
tion of prandial and/or basal insulin). The primary outcome of this study 
was the reduction of HbA1c.
I N T R O D U C T I O N
M E T H O D S
Both interventions consisted of 6 lessons (see table 1 with the key topics 
of the lessons). At baseline and follow-up, HbA1c was measured in a cen-
tral laboratory. Participants also completed questionnaires to measure di-
abetes distress, empowerment, diabetes knowledge and hypoglycaemia 
awareness.
R E S U L T S
• 182 PWD-T2 participated in the study (see table 2 for baseline cha-
racteristics). There were no significant differences at baseline bet-
ween MEDIAS 2 BSC and CG. At the 6-month follow-up, data of 160 
participants could be analysed.
• 17 participants were lost to follow-up and 5 participants terminated 
insulin treatment (see figure 1). Patients who were lost to follow-
up or terminated insulin treatment were significantly younger than 
participants of the per protocol population. 
• HbA1c was significantly more reduced in MEDIAS 2 BSC compared 
to CG (-0.7 ±0.1 vs. -0.3 ±0.1%; p=.02 (see figure 2).  Figure 3 shows 
the effect of MEDIAS 2 BSC in the per-protocol- and intention-to-
treat-population (baseline HbA1c  carried forward for participants 
who were lost to follow-up). All analyses showed a significant bene-
fit of MEDIAS 2 BSC with regard to glycaemic control. 
• There was no severe hypoglycaemic event reported (medical assis-
tance required) in neither treatment group.  Hypoglycaemia una-
wareness measured by questionnaire did not change significantly in 
the two groups. Thus, reductions in HbA1c was not associated with 
an increased risk of severe hypoglycaemia (see figure 4).
• In both intervention groups there was an improvement of Diabetes 
Self Care, Knowledge, Diabetes Distress, Depression and Health Re-
lated Quality of Life. However, the differences between MEDIAS 2 
C O N C L U S I O N
Participation in the newly developed MEDIAS 2 BOT+SIT+CT treatment 
and education programme led to a significant improvement of glycaemic 
control without a measurable increase in risk for hypoglycaemia. An im-
portant component of the newly developed MEDIAS 2 BOT+SIT+CT was 
self-titration of insulin doses; this might have contributed to the positi-
ve impact of this programme on glycaemic control. There was a positive 
impact of diabetes education delivered either in the control group or in 
the MEDIAS 2 BSC group on Diabetes Self-Care activities, Diabetes Know-
ledge, Diabetes Distress, Depressive Symptoms and Health-Related Quali-
ty of Life. However, the impact of the different education programmes on 
these psychosocial outcomes was too small to reach significance with re-
gard to between group differences. Participants in the study had a rather 
high age and long diabetes duration and were highly affected by diabetes 
complications. This might have limited beneficial effects of diabetes edu-
cation on depressive symptoms, diabetes distress and health-related qua-
lity of life. Treatment factors did not differ substantially between MEDIAS 
2 BSC and the control group. The sensitivity analysis controlling for mode 
of insulin treatment or insulin dose suggests that the beneficial impact of 
MEDIAS 2 BSC on glycemic control was not explained by treatment inten-
sification or mode of insulin treatment.
In summary, MEDIAS 2 BOT+SIT+CT has been proven as an effective treat-
ment and education tool.
Table 3:  Impact of MEDIAS 2 BSC and CG von Diabetes Self Care, Knowledge, Diabe-
tes Distress, Depression and Health-Related  Quality of Life (adjusted for stu-
dy centre)
Figure 1:  Consort statement: study flow
Table 1:  Content of education programmes in CG and MEDIAS 2 BOT+SIT+CT
BSC and CG were not significant (see table 3).
• Number of insulin injections or blood glucose self-tests as well as in-
sulin doses were only slightly changed during the intervention and 
follow-up period in both groups. There was a moderate increase of 
weight in both groups. Between groups differences did not reach 
significance (see table 4).
• A sensitivity analysis evaluated whether treatment differences like 
insulin doses, number of insulin injections or change of insulin re-
gimen had an impact on the observed HbA1c difference in both 
groups. The results of these sensitivity analyses are shown in figure 
5.
Randomised (n=182)
Control Group
(n=90)
MEDIAS 2 BOT+SIT+CT
(n=92)
6 months follow‐up:
per protocol analysis
78 participants
6 months follow‐up:
per protocol analysis
82  participants
8 participants „lost to follow‐up“
4 terminated insulin treatment
9 participants „lost to follow‐up“
1 terminated insulin treatment
Figure 5:  Sensitivity analysis of the impact of treatment factors on HbA1c differen-
ces between both groups
Table 4: Impact of MEDIAS 2 BOT+SIT+CT and CG on treatment factors (adjusted for 
study centre)
Figure 2: Effects of MEDIAS 2 BOT+SIT+CT and CG on HbA1c (adjusted for study 
centre)
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Figure 4:  Effects of MEDIAS 2 BOT+SIT+CT and CG on Hypoglycaemia Unawareness
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Figure 3:  Effects of MEDIAS 2 BOT+SIT+CT and CG on HbA1c in per protocoll and  in-
tention to treat population
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Table 2:  Sample characteristics
1 BOT +: Insulin treatment regimen with one or 2 injects of basal insulin and one fixed dose of prandial insulin 
2 One of the following complications: retinopathy, neuropathy, nephropathy, stroke, cardiovascular disease, diabetic foot syndrome, 
peripheral vascular disease. 
